What is the effect of letrozole on endometriosis in a reproductive‑age woman planning IVF, and how should it be incorporated into the ovarian stimulation protocol?

Letrozole Co-Treatment in Endometriosis Before IVF

Letrozole co-treatment with gonadotropins during IVF ovarian stimulation in women with endometriosis significantly reduces gonadotropin requirements and estradiol levels while maintaining comparable pregnancy outcomes to conventional protocols.

Mechanism and Rationale

Letrozole is an aromatase inhibitor that suppresses estrogen biosynthesis by 75-95% within 2-3 days 1. In endometriosis, where the disease is estrogen-dependent, reducing circulating estradiol during ovarian stimulation theoretically minimizes disease stimulation while achieving adequate follicular development 2.

Evidence for Use in Endometriosis-Associated Infertility

IVF Ovarian Stimulation Protocol

The combination of letrozole (2.5-5 mg daily for 5 days starting cycle day 3) plus gonadotropins produces equivalent oocyte and embryo yields compared to gonadotropin-only protocols, with significant advantages:

• Reduced gonadotropin dose: Significantly lower total gonadotropin consumption without decreasing oocyte retrieval numbers 3, 4
• Lower peak estradiol: Estradiol levels reduced by approximately 67% (722 vs 2168 pg/mL, p<0.001) 4
• Comparable pregnancy rates: No significant difference in biochemical or clinical pregnancy rates between letrozole co-treatment and conventional protocols 3
• Similar embryo outcomes: Fertilization rates and number of embryos obtained remain unchanged 4

Specific Protocol Details

The most studied approach involves:

1. Long GnRH agonist protocol initiated in mid-luteal phase
2. Letrozole 5 mg daily from cycle day 3-7
3. Gonadotropins started on cycle day 3, with doses adjusted based on age, AMH, and FSH
4. Standard monitoring and HCG trigger when follicles mature 3

One caveat: The percentage of mature oocytes may be slightly lower with letrozole co-treatment (69.9% vs 80.2%, p=0.029) 4, though this doesn't translate to reduced pregnancy rates.

Broader Context: Poor Responders vs Normal Responders

While your question focuses on endometriosis, the meta-analysis evidence shows letrozole's benefits vary by patient type 5:

• Poor responders: Live birth rate increases by 7% (95% CI: 1-13%, p=0.03) with letrozole co-treatment
• Normal responders: Increased oocyte yield (+1.8 oocytes) but no demonstrated improvement in live birth rates
• Endometrium: Slight reduction in endometrial thickness noted across studies, though not clinically significant for pregnancy outcomes 5

Alternative Consideration: Ovulation Induction Post-Laparoscopy

For women with minimal-to-mild endometriosis who undergo operative laparoscopy first, letrozole ovulation induction (without IVF) shows an 88.7% ovulation rate but does not significantly improve pregnancy rates over laparoscopy alone (38.6% cumulative pregnancy at 12 months vs 31.4% control) 6. This suggests that for endometriosis patients, proceeding directly to IVF with letrozole co-treatment may be more efficient than attempting ovulation induction alone.

Clinical Implementation Algorithm

For reproductive-age women with endometriosis planning IVF:

1. Initiate standard long agonist protocol (or antagonist protocol per institutional preference)
2. Add letrozole 5 mg daily on cycle days 3-7 when starting gonadotropins
3. Reduce initial gonadotropin dose by approximately 25-30% compared to standard protocols, as letrozole enhances follicular response
4. Monitor estradiol levels: Expect significantly lower peak levels (target <1000 pg/mL vs typical 2000+ pg/mL)
5. Proceed with standard trigger and retrieval when adequate follicular development achieved

Important Caveats

• FDA approval: Letrozole is FDA-approved only for breast cancer treatment 1; its use in fertility is off-label
• Neonatal outcomes: None of the IVF studies reported neonatal safety data 5, though extensive ovulation induction literature supports safety
• Cost-effectiveness: Letrozole significantly reduces treatment costs through decreased gonadotropin requirements 3, 7
• No OHSS cases reported in letrozole co-treatment protocols for endometriosis 8

The primary advantage is maintaining low estrogen exposure during stimulation—theoretically beneficial in estrogen-sensitive endometriosis—while achieving equivalent reproductive outcomes with reduced medication costs and potentially less disease stimulation.